| Price | $106.80 on 23-09-2026 at 18:35:06 |
|---|---|
| Change | $5.40 5.26% |
| Buy | $109.20 |
| Sell | $107.00 |
| Last Trade: | Sell 54.00 at $106.80 |
| Day's Volume: | 8,831 |
| Last Close: | $108.10 |
| Open: | $105.40 |
| ISIN: | XS3005160091 |
| Day's Range | $100.00 - $119.60 |
| 52wk Range: | $3.105 - $122.00 |
| Market Capitalisation: | $N/A |
| VWAP: | $110.64915 |
| Shares in Issue: | N/A |
3x Long Mrna (MRN3) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Sell* | 54 | $106.80 | Automatic Execution |
15:58:31 - 23-Sep-26 |
| Buy* | 60 | $111.60 | Automatic Execution |
15:47:42 - 23-Sep-26 |
| Buy* | 471 | $112.00 | Automatic Execution |
15:47:40 - 23-Sep-26 |
| Buy* | 100 | $111.60 | Automatic Execution |
15:47:40 - 23-Sep-26 |
| Buy* | 265 | $111.60 | Automatic Execution |
15:47:40 - 23-Sep-26 |
| Sell* | 50 | $109.00 | Automatic Execution |
15:45:45 - 23-Sep-26 |
| Sell* | 33 | $109.00 | Automatic Execution |
15:42:41 - 23-Sep-26 |
| Sell* | 178 | $109.00 | Automatic Execution |
15:42:41 - 23-Sep-26 |
| Sell* | 26 | $109.40 | Automatic Execution |
15:40:19 - 23-Sep-26 |
| Sell* | 550 | $109.60 | Automatic Execution |
15:40:19 - 23-Sep-26 |
3x Long Mrna (MRN3) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 20th Aug 2026 3:33 pm | RNS | Intraday Rebalance - 3x Long Moderna (MRNA) |
| 26th Feb 2025 3:28 pm | RNS | 3x MRNA - Consolidation Notice |
| 26th Feb 2025 3:24 pm | RNS | Result of ETP Securityholder Meeting - 3x MRNA |
| 11th Feb 2025 1:04 pm | RNS | Notice of Adjourned Meeting - 3x MRNA |
| 17th Jan 2025 3:09 pm | RNS | ETP Securityholder Mtg 3x Moderna |
| 13th Jan 2025 3:06 pm | RNS | 3x MRNA Intraday Rebalance Notice |
| 12th Sep 2024 3:04 pm | RNS | Leverage Shares - Intraday Rebalance 3x MRNA |
| 30th Aug 2023 5:41 pm | RNS | Leverage Shares Consolidation Update |
| 23rd Aug 2023 5:11 pm | RNS | Consolidation Update 23 August 2023 |
| 21st Jul 2023 4:43 pm | RNS | Result adjourn meet LS 3xLong Moderna(MRNA)ETP Ses |
